ChinaHealthcare and life sciences2025 – ongoingInnovent Biologics
AI and next-generation sequencing for antibody discovery
Innovent reported 75-90% antibody-discovery accuracy with AI and sequencing
Problem
Experimental antibody screening had limited throughput and high costs. Sequencing-based selection alone produced inconsistent binding predictions.
Approach
Innovent trained classifiers to distinguish positive and negative antibody clones using sequencing data. It integrated AI predictions into an automated WeMol-based screening workflow. Its laboratory and computational platform was applied to multiple internal projects.
Results
Takeaway
Computational screening remained connected to experimental validation. Innovent reported shorter screening cycles without disclosing the time saved.
Categories
- Industry
- Healthcare and life sciences
- Business function
- IT and R&D
- Innovation type
- Process innovation
- AI technology
- Predictive analytics and ML
- Adoption
- Off-the-shelf tool or platform
- Evidence
- Vendor case study
Sources
Source summaries
Innovent reported internal use of its AI and sequencing antibody platform. It claimed shorter screening cycles without quantified time savings.
Wecomput recounted an Innovent executive's presentation on its WeMol-based antibody screening platform. The executive reported classification models integrated into automated workflows and antibody-discovery accuracy of 75-90%.
Full details are in the original sources.